Nutarniq joins Health 2 Innovation (H2i) Accelerator
Nutarniq has been accepted into the Health 2 innovation (H2i) accelerator at the U of T Faculty of Medicine. H2i supports companies that have the developed innovative solutions to transform health through scientific / biomedical innovation.
“Nutarniq is a great fit for the H2i program”, said Dr. Evan Lewis, Nutarniq CEO. “We are focused on using our omega-3 supplement Nutarniq Essentials as a solution to stop the progression of diabetic neuropathy, and my clinical research is the first to show this is possible.”
Dr. Lewis’ research is the first to show a therapy that can stop the progression of diabetic neuropathy. Currently, there are no therapies that can stop or reverse the progression this disease. By working with H2i, Nutarniq will gain exposure to more individuals with and at risk of diabetic neuropathy as well as clinicians within the University Health Network that work with these patients on a daily basis.
Find out how Nutarniq Essentials is helping people with diabetes and pre-diabetes HERE.
Learn more about Nutarniq HERE.